Genomic Health, Inc.

Nsabp Foundation, Inc.

Nodality, Inc.

Nsabp Foundations, Inc.

James Hackett

Joffre B Baker

Soonmyung Paik

Wayne Cowens

Drew Watson

Kim Clark

Michael C Kiefer

Michael D Walker

Wendy Fantl

David B Rosen

Santosh K Putta

Alessandra Cesano

Kim Langone

Jing Shi

Kim Clark-Langane

The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.

Genes involved in estrogen metabolism

The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.

Gene expression markers for prediction of patient response to chemotherapy

The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.

Methods for diagnosis, prognosis and methods of treatment

A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

Gene expression markers for colorectal cancer prognosis

Genes involved estrogen metabolism

Growing community of inventors

San Jose, CA, United States of America

James Hackett